Ractigen Therapeutics
PrivateLast Round
Early Funding
Jul 29, 2026
Total Funding Raised
$78M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Ractigen Therapeutics is a clinical-stage pharmaceutical company creating first-in-class therapies designed to boost expression of therapeutic genes in diseased cells using RNA activation (RNAa) technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ractigen Therapeutics Comparables
Compare Ractigen Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MiNA Therapeutics | 85% | |
| CAMP4 | 73% | |
| Shape Therapeutics | 72% |
Ractigen Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Jul 29, 2026 | ||||
| Series A Extension | Jan 27, 2022 | ||||
| Series A | Feb 10, 2021 |
Key People
Founding team and executive leadership
Ractigen Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IDG Capital | Early Funding |
| Boyu Capital | Series A |
| Longmen Capital | Early Funding |
| Hillhouse Investment | Series A |
| Huimei Capital | Series A |
| CCB International | Series A |
| SDIC Venture Capital | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
$31M raised from IDG Capital and others.
- Jan 20, 2026
Monthly visitors increased 256% MoM.
Recent news
Latest coverage and updates
- attends_eventSep 15, 2026
Ractigen Therapeutics will attend event 31st Annual Congress of the World Muscle Society on Sep 29th '26.
- receives_financingJul 29, 2026
Ractigen Therapeutics received financing of $31M in Series A Plus on Jul 29th '26.
Ractigen Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ractigen Therapeutics's valuation, stock price, and market status.
Is Ractigen Therapeutics a public or private company?
Ractigen Therapeutics is a private company.
What is the current stock price of Ractigen Therapeutics?
Ractigen Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Ractigen Therapeutics worth (valuation)?
Valuation information for Ractigen Therapeutics is not publicly available.
Can I buy Ractigen Therapeutics stock?
Ractigen Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ractigen Therapeutics's last funding round?
Ractigen Therapeutics's most recent funding round was Series A Extension on January 27, 2022.
Who are the main investors in Ractigen Therapeutics?
Key investors in Ractigen Therapeutics include Hillhouse Investment, SDIC Venture Capital.
Will Ractigen Therapeutics IPO soon?
No public IPO plans have been announced for Ractigen Therapeutics.
How can I track Ractigen Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ractigen Therapeutics's secondary market activity and sign up for updates.